{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:35:18Z","timestamp":1793406918894,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":232,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017065","name":"University of Michigan Rogel Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Michigan Kellogg Eye Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Basal cell carcinoma (BCC) is a common skin cancer often curable by excision; however, for patients with BCC around the eye, excision places visual organs and function at risk. In this article, we test the hypothesis that use of the hedgehog inhibitor vismodegib will improve vision-related outcomes in patients with orbital and extensive periocular BCC (opBCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>In this open-label, nonrandomized phase IV trial, we enrolled patients with globe- and lacrimal drainage system\u2013threatening opBCC. To assess visual function in the context of invasive periorbital and lacrimal disease, we used a novel Visual Assessment Weighted Score (VAWS) in addition to standard ophthalmic exams. Primary endpoint was VAWS with a score of 21\/50 (or greater) considered successful, signifying globe preservation. Tumor response was evaluated using RECIST v1.1. Surgical specimens were examined histologically by dermatopathologists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 34 patients with opBCC, mean VAWS was 44\/50 at baseline, 46\/50 at 3 months, and 47\/50 at 12 months or postsurgery. In total, 100% of patients maintained successful VAWS outcome at study endpoint. Compared with baseline, 3% (95% confidence interval [CI], 0.1\u201315.3) experienced major score decline (5+ points), 14.7% (95% CI, 5 to 31.1) experienced a minor decline (2\u20134 points), and 79.4% experienced a stable or improved score (95% CI, 62.1\u201391.3). A total of 56% (19) of patients demonstrated complete tumor regression by physical examination, and 47% (16) had complete regression by MRI\/CT. A total of 79.4% (27) of patients underwent surgery, of which 67% (18) had no histologic evidence of disease, 22% (6) had residual disease with clear margins, and 11% (3) had residual disease extending to margins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vismodegib treatment, primary or neoadjuvant, preserves globe and visual function in patients with opBCC. Clinical trail identification number.NCT02436408.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>Use of the antihedgehog inhibitor vismodegib resulted in preservation of end-organ function, specifically with regard to preservation of the eye and lacrimal apparatus when treating extensive periocular basal cell carcinoma. Vismodegib as a neoadjuvant also maximized clinical benefit while minimizing toxic side effects. This is the first prospective clinical trial to demonstrate efficacy of neoadjuvant antihedgehog therapy for locally advanced periocular basal cell carcinoma, and the first such trial to demonstrate end-organ preservation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/onco.13820","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T09:10:28Z","timestamp":1620983428000},"page":"e1240-e1249","source":"Crossref","is-referenced-by-count":37,"title":["Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5667-2274","authenticated-orcid":false,"given":"Alon","family":"Kahana","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Consultants in Ophthalmic and Facial Plastic Surgery, Southfield, Michigan, USA"},{"name":"Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-8187","authenticated-orcid":false,"given":"Shelby P.","family":"Unsworth","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May P.","family":"Chan","sequence":"additional","affiliation":[{"name":"Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2504-466X","authenticated-orcid":false,"given":"Scott C.","family":"Bresler","sequence":"additional","affiliation":[{"name":"Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Bichakjian","sequence":"additional","affiliation":[{"name":"Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison B.","family":"Durham","sequence":"additional","affiliation":[{"name":"Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Demirci","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7708-1898","authenticated-orcid":false,"given":"Victor M.","family":"Elner","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine C.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise S.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon S.","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-3555","authenticated-orcid":false,"given":"Paul L.","family":"Swiecicki","sequence":"additional","affiliation":[{"name":"Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Section on Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis P.","family":"Worden","sequence":"additional","affiliation":[{"name":"Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Section on Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"2022020214212573300_onco13820-bib-0001","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2022020214212573300_onco13820-bib-0002","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/bjophthalmol-2015-308261","article-title":"Incidence of eyelid basal cell carcinoma in England: 2000-2010","volume":"101","author":"Saleh","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"2022020214212573300_onco13820-bib-0003","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/S0140-6736(04)17399-6","article-title":"Surgical excision vs Mohs\u2019 micrographic surgery for basal-cell carcinoma of the face: Randomised controlled trial","volume":"364","author":"Smeets","year":"2004","journal-title":"Lancet"},{"key":"2022020214212573300_onco13820-bib-0004","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/bjd.17516","article-title":"Recurrence of periocular basal cell carcinoma and squamous cell carcinoma after Mohs micrographic surgery: A retrospective cohort study","volume":"180","author":"Weesie","year":"2019","journal-title":"Br J Dermatol"},{"key":"2022020214212573300_onco13820-bib-0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0002-9394(14)71523-5","article-title":"Clinical characteristics associated with orbital invasion of cutaneous basal cell and squamous cell tumors of the eyelid","volume":"113","author":"Howard","year":"1992","journal-title":"Am J Ophthalmol"},{"key":"2022020214212573300_onco13820-bib-0006","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ophtha.2004.11.036","article-title":"Orbital invasion by periocular basal cell carcinoma","volume":"112","author":"Leibovitch","year":"2005","journal-title":"Ophthalmology"},{"key":"2022020214212573300_onco13820-bib-0007","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1097\/SCS.0000000000003242","article-title":"Periocular basal cell carcinoma predictors for recurrence and infiltration of the orbit","volume":"28","author":"Furdova","year":"2017","journal-title":"J Craniofac Surg"},{"key":"2022020214212573300_onco13820-bib-0008","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2217\/fon.15.190","article-title":"Management of periorbital basal cell carcinoma with orbital invasion","volume":"11","author":"Sun","year":"2015","journal-title":"Future Oncol"},{"key":"2022020214212573300_onco13820-bib-0009","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.2147\/OTT.S130371","article-title":"Ocular basal cell carcinoma: A brief literature review of clinical diagnosis and treatment","volume":"10","author":"Shi","year":"2017","journal-title":"Onco Targets Ther"},{"key":"2022020214212573300_onco13820-bib-0010","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1126\/science.272.5268.1668","article-title":"Human homolog of patched, a candidate gene for the basal cell nevus syndrome","volume":"272","author":"Johnson","year":"1996","journal-title":"Science"},{"key":"2022020214212573300_onco13820-bib-0011","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/34201","article-title":"Activating Smoothened mutations in sporadic basal-cell carcinoma","volume":"391","author":"Xie","year":"1998","journal-title":"Nature"},{"key":"2022020214212573300_onco13820-bib-0012","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-12-1956","article-title":"U.S. Food and Drug Administration approval: Vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma","volume":"19","author":"Axelson","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022020214212573300_onco13820-bib-0013","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"2022020214212573300_onco13820-bib-0014","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"Von Hoff","year":"2009","journal-title":"N Engl J Med"},{"key":"2022020214212573300_onco13820-bib-0015","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1113538","article-title":"Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome","volume":"366","author":"Tang","year":"2012","journal-title":"N Engl J Med"},{"key":"2022020214212573300_onco13820-bib-0016","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","article-title":"Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022020214212573300_onco13820-bib-0017","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2014.05.020","article-title":"An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma","volume":"71","author":"Ally","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2022020214212573300_onco13820-bib-0018","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaad.2016.02.1235","article-title":"Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC)","volume":"75","author":"Kwon","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2022020214212573300_onco13820-bib-0019","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2015.03.013","article-title":"A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma","volume":"73","author":"Sofen","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2022020214212573300_onco13820-bib-0020","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamaophthalmol.2013.4430","article-title":"Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma","volume":"131","author":"Kahana","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"2022020214212573300_onco13820-bib-0021","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/IOP.0000000000001166","article-title":"Neoadjuvant Vismodegib and mohs micrographic surgery for locally advanced periocular basal cell carcinoma","volume":"35","author":"Gonz\u00e1lez","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2022020214212573300_onco13820-bib-0022","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ajo.2019.04.013","article-title":"Efficacy of vismodegib for the treatment of orbital and advanced periocular basal cell carcinoma","volume":"207","author":"Eiger-Moscovich","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"2022020214212573300_onco13820-bib-0023","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/bjophthalmol-2018-312277","article-title":"Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma","volume":"103","author":"Sagiv","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"2022020214212573300_onco13820-bib-0024","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jamaophthalmol.2013.5018","article-title":"Vismodegib for periocular and orbital basal cell carcinoma","volume":"131","author":"Gill","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"2022020214212573300_onco13820-bib-0025","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamaophthalmol.2020.1539","article-title":"Outcomes of vismodegib for periocular locally advanced basal cell carcinoma from an open-label trial","volume":"138","author":"Ben Ishai","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"2022020214212573300_onco13820-bib-0026","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2022020214212573300_onco13820-bib-0027","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1586\/14737140.2.5.570","article-title":"Environment, phenotype and genetics: Risk factors associated with BCC of the skin","volume":"2","author":"Hoban","year":"2002","journal-title":"Expert Rev Anticancer Ther"},{"key":"2022020214212573300_onco13820-bib-0028","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ijc.24327","article-title":"Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians","volume":"125","author":"Nan","year":"2009","journal-title":"Int J Cancer"},{"key":"2022020214212573300_onco13820-bib-0029","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccell.2017.12.015","article-title":"Tumor architecture and Notch signaling modulate drug response in basal cell carcinoma","volume":"33","author":"Eberl","year":"2018","journal-title":"Cancer Cell"},{"key":"2022020214212573300_onco13820-bib-0030","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1755-3768.2010.02092.x","article-title":"Quality of life of eye amputated patients","volume":"90","author":"Rasmussen","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"2022020214212573300_onco13820-bib-0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136460","article-title":"Vision-related quality of life and appearance concerns are associated with anxiety and depression after eye enucleation: A cross-sectional study","volume":"10","author":"Ye","year":"2015","journal-title":"PLoS One"},{"key":"2022020214212573300_onco13820-bib-0032","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/eye.2016.218","article-title":"Orbital exenteration for advanced periorbital non-melanoma skin cancer: Prognostic factors and survival","volume":"31","author":"Gerring","year":"2017","journal-title":"Eye (Lond)"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13820","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13820","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/7\/e1240\/42367481\/oncolo_26_7_e1240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/7\/e1240\/42367481\/oncolo_26_7_e1240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T09:22:07Z","timestamp":1643793727000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/7\/e1240\/6510480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,5,31]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13820","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,5,31]]}}}